Table 3.

Serum lipid levels over time in the five experimental groupsa

Experimental groupsNumber of subjectsTotal cholesterol (mg/dL)LDL cholesterol (mg/dL)HDL cholesterol (mg/dL)Triglycerides (mg/dL)
Group 1. Control
 Baseline53207.3 ± 43.18114 ± 38.0768.75 ± 18.83122.7 ± 54.57
 12 months48208.8 ± 34.39115.1 ± 31.9970.71 ± 18.87114.5 ± 62.95
 24 months47207.5 ± 36.41115.3 ± 29.2170.19 ± 19.35110.1 ± 44.25
Group 2. Raloxifene 60 mg
 Baseline51203.6 ± 29.98114.7 ± 27.5366.18 ± 15.47113.2 ± 48.39
 12 months42198.3 ± 29.33106.8 ± 25.98b68.88 ± 14.06113.2 ± 55.08
 24 months38196.6 ± 30.64104.7 ± 28.13c68.63 ± 15.04116.9 ± 50.17b
Group 3. Raloxifene 30 mg
 Baseline52204.3± 36.29111.2 ± 31.8370.92 ± 18.54110.6 ± 50.49
 12 months41199.6 ± 28.43106.2 ± 24.3870.59 ± 16.63113.7 ± 49.76
 24 months36202.3 ± 25.58106.1 ± 25.473.17 ± 18.01115.8 ± 58.48
Group 4. Lovaza 4 g
 Baseline54197.7 ± 33.2106.6 ± 31.9668.06 ± 16.89115.1 ± 52.33
 12 months51199.6 ± 30.45109.7 ± 29.2270.59 ± 18.3196.22 ± 42.94
 24 months49200.2 ± 34.55110.4 ± 29.270.67 ± 19.3895.41 ± 49.6b
Group 5. Lovaza 4 g plus raloxifene 30 mg
 Baseline52197.6 ± 38.68108.1 ± 35.8768.9 ± 17.68103.6 ± 38.79
 12 months45189.4 ± 33.45c96.58 ± 26.37c76.11 ± 18.61b83.71 ± 31.08c
 24 months44192.6 ± 30.0299.48 ± 25.2b75.77 ± 17.8b86.43 ± 35b
  • aData represent mean ± SD.

  • bP < 0.05 versus control.

  • cP < 0.01 versus control.